Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGS-1C4D4 plus gemcitabine in metastatic pancreatic cancer
2009-009194-99Phase 2Terminated
- Sponsor
- Agensys, Inc.
- Start
- Feb 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic cancer (PDAC) comparing AGS-1C4D4 + gemcitabine with Gemcitabine alone (2 arms). Primary endpoint: 6-month survival status. Started Feb 2010; status: terminated.
02
Drugs
AGS-1C4D4gemcitabine
03
Conditions
pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2009-009194-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009194-99.